Back

Effect of sglt2-inhibitors on polygraphic parameters in elderly patients affected by heart failure and sleep apnea

11 May 2024 (08:00 - 20:00)
Organised by: Logo
Congress Presentation Part of: Acute heart failure 2 Multidisciplinary Interventions HFA Premium Access Heart Failure 2024 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Giulia Crudo

Magna Graecia University of Catanzaro, Catanzaro (Italy)

5 More presentations in this session

Presentation thumbnail
Could combined diuretic therapy increase decongestion in patients with acute heart failure?
Doctor B. Resende (Coimbra, PT)
Abstract Slides Video
Presentation thumbnail
Acute heart failure patients with diuretic resistance: who are they and prognostic implications of diuretic resistance. The experience of a general hospital
Doctor G. Aletras (Heraklion, GR)
Abstract Slides Video
Presentation thumbnail
Artificial intelligence-based risk stratification model for patients hospitalized for acute heart failure
Doctor K. Lorlowhakarn (Bangkok, TH)
Abstract Slides Video
Presentation thumbnail
An integer-based diuresis score for detecting diuretic resistance in acute heart failure: implications for clinical events
Ms L. Burgos (Buenos Aires, AR)
Abstract Slides Video
Presentation thumbnail
Improving heart failure medication initiation and optimisation inline with International guidelines.
Mrs M. JOY (Waterford, IE)
Abstract Slides Video

Access the full session

Session thumbnail
Acute heart failure 2

The Event

Event poster

Heart Failure 2024

11 May - 14 May 2024
You may be interested in
thumbnail
Congress Presentation
Cardiometabolic benefits of dual GLP1-RA and SGLT2i therapy in patients with HFpEF, T2DM, obesity, and obstructive sleep apnea: a prospective study
thumbnail
Congress Presentation
Right vs. left cardiac function and structure: impact of SGLT2i in acute decompensate heart failure with central sleep apnea
thumbnail
Congress Presentation
The effect of GLP-1 receptor agonists on obstructive sleep apnea in ambulatory patients with HFpEF, obesity, and type 2 diabetes.

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources